| Autologous platelet rich plasma (A-PRP) combined with pelvic floor muscle training for the treatment of female stress urinary incontinence (SUI): A randomized control clinical trial.Neurourol Urodyn | PMID 38108468无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intrarectal injections of botulinum toxin versus placebo for the treatment of urge faecal incontinence in adults (FI-Toxin): a double-blind, multicentre, randomised, controlled phase 3 study.Lancet Gastroenterol Hepatol | PMID 38128556无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.Lancet Oncol | PMID 38134948无 PMCID | 2024-Feb | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.Lancet HIV | PMID 38141637无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Haematol | PMID 38142695无 PMCID | 2024-Feb | 0.85 | The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, it does not have a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) as required; the primary endpoint is a proportional outcome (incidence of CMV infection). | 待处理 |
| Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction (ADVENT-HF): a multicentre, multinational, parallel-group, open-label, phase 3 randomised controlled trial.Lancet Respir Med | PMID 38142697无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.Lancet Oncol | PMID 38142702无 PMCID | 2024-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.J Neurooncol | PMID 38153582无 PMCID | 2024-Feb | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial.Lancet Respir Med | PMID 38184010无 PMCID | 2024-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial.Mol Genet Metab | PMID 38184428无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies.Epilepsy Behav | PMID 38184949无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.Lung Cancer | PMID 38198859无 PMCID | 2024-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials.Clin Ther | PMID 38216351无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).Lung Cancer | PMID 38224653无 PMCID | 2024-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial.Lancet Oncol | PMID 38224701无 PMCID | 2024-Feb | 0.95 | The study meets most criteria (oncology, human, randomized, phase 3, drug intervention, original result) but the primary efficacy endpoint is complete control (a binary outcome at 120 hours), not a time-to-event endpoint like OS or PFS, and no Kaplan-Meier survival analysis or hazard ratio for a time-to-event outcome is reported. | 待处理 |
| Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Glob Health | PMID 38245116无 PMCID | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.Lancet Haematol | PMID 38302221无 PMCID | 2024-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: a single-masked, phase 3, superiority, randomised controlled trial.Lancet Healthy Longev | PMID 38310894PMC10834374 | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.Influenza Other Respir Viruses | PMID 38314063PMC10837780 | 2024-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| PACE: randomized, controlled, multicentre, multinational, phase III study of PLX-PAD for critical limb ischaemia in patients unsuitable for revascularization: randomized clinical trial.Br J Surg | PMID 38294084PMC10828925 | 2024-Jan-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The effects of synbiotic supplementation on blood pressure and other maternal outcomes in pregnant mothers with mild preeclampsia: a triple-blinded randomized controlled trial.BMC Womens Health | PMID 38297273PMC10829212 | 2024-Jan-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.BMC Cancer | PMID 38291372PMC10826080 | 2024-Jan-30 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.N Engl J Med | PMID 38078508无 PMCID | 2024-Jan-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J Med | PMID 38084760无 PMCID | 2024-Jan-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Detailed statistical analysis plan for ALBINO: effect of Allopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome - a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III).Trials | PMID 38267942PMC10809613 | 2024-Jan-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA).Curr Oncol | PMID 38392042PMC10888026 | 2024-Jan-24 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.Br J Dermatol | PMID 37939793无 PMCID | 2024-Jan-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.J Clin Oncol | PMID 37864337PMC10824389 | 2024-Jan-20 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.J Clin Oncol | PMID 37976444PMC10824371 | 2024-Jan-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | PMID 38048786无 PMCID | 2024-Jan-20 | 0.85 | The trial is a Phase 3 randomized controlled trial with a drug intervention and reports a primary efficacy endpoint (8-week RBC-TI rate). However, the primary endpoint is a binary proportion, not a time-to-event (e.g., OS, PFS) measure analyzed via Kaplan-Meier or hazard ratio. The study also reports durable transfusion independence (approximately 1 year) in the interpretation, but the primary and key secondary analyses as presented in the abstract are based on binary rates and safety, not time-to-event endpoints with the required statistical methods. Therefore, it does not meet the specific 'time-to-event efficacy endpoint' criterion. | 待处理 |
| Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.N Engl J Med | PMID 38231624PMC11156186 | 2024-Jan-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| HBV-miR-3 is closely related to HBV replication and strongly predictive of HBeAg seroconversion in PegIFN-α treated patients.Sci Rep | PMID 38233602PMC10794194 | 2024-Jan-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study.Arthritis Res Ther | PMID 38233885PMC10792872 | 2024-Jan-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.Trials | PMID 38229199PMC10790497 | 2024-Jan-16 | 0.55 | This is a protocol paper for an ongoing phase 3 randomized trial in oncology with a time-to-event endpoint (PFS), but it does not report completed trial results. The drug intervention involves CAM2029 (octreotide subcutaneous depot) versus standard-of-care somatostatin receptor ligands (octreotide LAR or lanreotide), which are drugs, but the abstract does not provide efficacy results from the completed trial. It is not an original formal result report. | 待处理 |
| Evaluation of the Efficacy and Safety of DW1903 in Patients with Gastritis: A Randomized, Double-Blind, Noninferiority, Multicenter, Phase 3 study.Gut Liver | PMID 37309193PMC10791492 | 2024-Jan-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study.J Clin Psychiatry | PMID 38236020无 PMCID | 2024-Jan-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.Lancet | PMID 38008109无 PMCID | 2024-Jan-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.Lancet | PMID 38104575无 PMCID | 2024-Jan-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.N Engl J Med | PMID 38197816无 PMCID | 2024-Jan-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.J Clin Oncol | PMID 37788412无 PMCID | 2024-Jan-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.J Clin Oncol | PMID 37906724PMC10824373 | 2024-Jan-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).J Clin Oncol | PMID 37906726无 PMCID | 2024-Jan-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.J Clin Oncol | PMID 38039427无 PMCID | 2024-Jan-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial.Antimicrob Agents Chemother | PMID 38095426PMC10869335 | 2024-Jan-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904).Jpn J Clin Oncol | PMID 37801434无 PMCID | 2024-Jan-07 | 0.65 | This is a protocol for an ongoing Phase III randomized trial in oncology with a primary time-to-event endpoint, but it does not present results. The eligibility criteria require original formal-result reports of completed trials. Additionally, the drug intervention (specific chemotherapy agent(s)) is not explicitly detailed in the provided record, which is needed to confirm a drug-containing intervention. | 待处理 |
| Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.Lancet | PMID 38048793无 PMCID | 2024-Jan-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial).Neuro Oncol | PMID 37417948PMC10768994 | 2024-Jan-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.Cancer Res Commun | PMID 38059497PMC10765772 | 2024-Jan-04 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.Clin Chem | PMID 38175595无 PMCID | 2024-Jan-04 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.JAMA | PMID 38078870PMC10714284 | 2024-Jan-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |